Skin Cancer

A 30-year-old patient with dermatofibrosarcoma protuberans faced a recurrence after initial surgery. Mohs micrographic surgery was used for precise excision, reducing recurrence risk and improving outcomes.

The expert discussion focused on patient management strategies, treatment modalities, and the role of multidisciplinary collaboration.

An analysis of 70 studies shows that MMS reduces local recurrence to 5.0% compared to 17.7% for WLE in anogenital SCC cases.

Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.

Satisfaction levels rose and recovery outcomes greatly improved with Cicaglocal compared to the placebo.

A dermatology expert panel confirms IGSRT as a safe, effective first-line treatment for select nonmelanoma skin cancer cases.

A recent study found sunscreen use is higher among women but often not reapplied properly.

A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or excessive hair.

Trauma-induced melanocyte implantation can lead to subcutaneous melanoma, mimicking melanoma of unknown primary but with distinct diagnostic criteria.

Study author Erin McClure, MD, discusses how IGSRT offers consistent NMSC recurrence rates across socioeconomic and comorbidity factors, reinforcing its role as a first-line treatment.

High concentrations of particulate matter can potentially lessen the exposure to UV radiation.

As newly appointed Executive Director of the Foundation, Becky Kamowitz is combining public education with clinical needs in the fight against skin cancer.

George Washington University recently earned a Skin Smart Campus designation, championing skin cancer prevention through education, free sunscreen, and UV safety measures.

Three posters supporting VP-315's treatment efficacy and outcomes were presented at the Winter Clinical Miami conference.

Explore the role of immunohistochemical stains in enhancing diagnostic accuracy during Mohs surgery, aiding treatment of challenging skin cancers.

Cemiplimab demonstrated a 68% reduction in recurrence risk for high-risk CSCC in the phase 3 C-POST trial, according to Regeneron’s latest findings.

Data augmentation techniques like cropping and blurring allow AI models to overcome limited datasets, improving skin cancer detection rates.

Post treatment discontinuation, most centers conduct imaging every 3 months during the first year of remission.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in skin cancer this year.

Join Dermatology Times’ quarterly editor in chief Aaron Farberg, MD, as he highlights significant advancements in gene expression profile testing for cutaneous melanoma.

Discover 2024 skin cancer breakthroughs, including FDA approvals, innovative therapies, and updated clinical guidelines for melanoma and nonmelanoma care.

Despite the risks of sun exposure, a study found only a fraction of coaches receive adequate UV-related guidance from their associations or clubs.

Researchers recommend limiting routine lipase tests to symptomatic patients or those with radiographic signs of pancreatic injury.

Certain factors may contribute to higher occurrences of non-melanoma skin cancer in these patients, according to a novel systemic review.

Pediatric melanoma, though rare, is the deadliest skin cancer in children, with 300-500 US cases annually.

Motivators like health benefits, altruism, and trust in clinicians enhance participant retention and adherence in melanoma research, according to MEL-SELF findings.

The study underscores the importance of addressing work-related concerns for patients with melanoma, advocating for effective communication about rehabilitation options.

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

In October's cover feature, Nicole A. Negbenebor, MD, FAAD, discusses the benefits of intralesional 5-fluorouracil injection for older patients with squamous cell carcinoma who may elect to delay therapy or are not ideal candidates for surgery.

Farberg discusses data recently published in Geriatrics demonstrating low rates of recurrence.